Continuing Single-Agent Capecitabin As Maintenance Therapy After Induction Of Xelox (Or Folfox) In First-Line Treatment Of Metastatic Colorectal Cancer

Rui-hua Xu,Yu-Hong Li,Huiyan Luo,Wei Wang,Zhi Qiang Wang,Xia Yuan,Fenghua Wang,Dong-Sheng Zhang,Dong Ma,Da Ren Lin,Jun Jia,Xiao-hua Hu,Jie Wen Peng
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.3580
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:3580 Background: Colorectal cancer (CRC) is one of the most common malignant tumors. All advanced CRC will progress after first-line treatment. Therefore, it is emergent to seek an efficient and low toxic maintaining regimen to prolong progression free survival (PFS). Some clinical researches demonstrated that maintaining treatment followed first-line treating could extend PFS. Our previous non-randomized small sample study indicated that patients receiving first-line treatment of XELOX followed by capecitabine as maintaining therapy had significantly prolonged median time to progression (TTP). Therefore, we plan to initiate the first randomized study to evaluate the efficacy and safety of maintenance therapy with capecitabine following induction of (XELOX) or (FOLFOX) versus observation until progression in first-line therapy in metastatic CRC. Methods: This is a multi-center, randomized phase III study. Patients who received 18-22 weeks chemotherapy with XELOX or FOLFOX and achieved objective response o...
What problem does this paper attempt to address?